|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
These results suggest the involvement of PARP-2 or other PARPs, in the repair of DNA damage provoked by methylating agents, highlighting the importance of targeting both PARP-1 and PARP-2 for cancer therapy.
|
20464779 |
2010 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
These results suggest the involvement of PARP-2 or other PARPs, in the repair of DNA damage provoked by methylating agents, highlighting the importance of targeting both PARP-1 and PARP-2 for cancer therapy.
|
20464779 |
2010 |
|
Azoospermia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The PARP-2 gene might be associated with azoospermia by meiotic arrest in humans.
|
19806447 |
2010 |
|
Lipodystrophy
|
0.300 |
Biomarker
|
disease |
CTD_human |
5-Benzamidoisoquinolin-1-ones and 5-(ω-carboxyalkyl)isoquinolin-1-ones as isoform-selective inhibitors of poly(ADP-ribose) polymerase 2 (PARP-2).
|
21417348 |
2011 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These have classically been with DNA damaging chemotherapy but the recently developed small molecule inhibitors of DNA repair enzymes such as Poly-ADP polymerases PARP-1 and PARP-2 have been shown to target tumour deficiencies in DNA repair as well sensitizing to DNA damaging therapeutics such as radiation and chemotherapy.
|
22015278 |
2011 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Furthermore, PARP-2(-/-) mice were protected against diet-induced obesity.
|
21459329 |
2011 |
|
Azoospermia
|
0.020 |
Biomarker
|
disease |
BEFREE |
PARP-2 was originally described in connection to DNA repair and in physiological and pathophysiological processes associated with genome maintenance (e.g., centromere and telomere protection, spermiogenesis, thymopoiesis, azoospermia, and tumorigenesis).
|
22581363 |
2012 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
PARP-2 was originally described in connection to DNA repair and in physiological and pathophysiological processes associated with genome maintenance (e.g., centromere and telomere protection, spermiogenesis, thymopoiesis, azoospermia, and tumorigenesis).
|
22581363 |
2012 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Our results show that LUDLU-1 lacks the mutational signature that has been previously associated with tobacco exposure in other lung cancer subtypes, and suggests that DNA-repair efficiency is adversely affected; LUDLU-1 contains somatic mutations in TP53 and BRCA2, allelic imbalance in the expression of two cancer-associated BRCA1 germline polymorphisms and reduced transcription of a potentially endogenous PARP2 inhibitor.
|
24244370 |
2013 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Our results show that LUDLU-1 lacks the mutational signature that has been previously associated with tobacco exposure in other lung cancer subtypes, and suggests that DNA-repair efficiency is adversely affected; LUDLU-1 contains somatic mutations in TP53 and BRCA2, allelic imbalance in the expression of two cancer-associated BRCA1 germline polymorphisms and reduced transcription of a potentially endogenous PARP2 inhibitor.
|
24244370 |
2013 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Niraparib (MK4827) is an oral potent, selective PARP-1 and PARP-2 inhibitor that induces synthetic lethality in preclinical tumour models with loss of BRCA and PTEN function.
|
23810788 |
2013 |
|
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Significant associations between polymorphisms and breast cancer risk were found for one SNP in PARP2 and three SNPs in the mitochondrial DNA polymerase gamma, POLG.
|
22684821 |
2013 |
|
Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Significant associations between polymorphisms and breast cancer risk were found for one SNP in PARP2 and three SNPs in the mitochondrial DNA polymerase gamma, POLG.
|
22684821 |
2013 |
|
Cardiomegaly
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Alpha-lipoic acid attenuates cardiac hypertrophy via downregulation of PARP-2 and subsequent activation of SIRT-1.
|
25281201 |
2014 |
|
Malignant Neoplasms
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Our data suggest for the first time that a SNP in PARP2, rs878156, may together with other genetic variants modulate cancer specific survival in breast cancer patients depending on chemotherapy.
|
26674097 |
2015 |
|
Primary malignant neoplasm
|
0.060 |
GeneticVariation
|
group |
BEFREE |
Our data suggest for the first time that a SNP in PARP2, rs878156, may together with other genetic variants modulate cancer specific survival in breast cancer patients depending on chemotherapy.
|
26674097 |
2015 |
|
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
|
26674097 |
2015 |
|
Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
|
26674097 |
2015 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
The maternal genotypes of single nucleotide polymorphisms in the excision repair cross-complementation group 1 (ERCC1), poly (ADP-ribose) polymerase 2 (PARP2), and ERCC5 genes were identified to be significantly associated with the occurrence of CHDs in the presence of maternal tobacco use.
|
26033827 |
2015 |
|
Solid Neoplasm
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors.
|
25757679 |
2015 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Positive PARP-2 and low miR-149 expression correlated with larger tumor mass size (P < 0.001), capsular and vascular invasion (P < 0.001), lymph node metastasis (P = 0.02), high histological grade (P < 0.001), TNM (P < 0.001), and BCLC grade (P = 0.001).
|
27300349 |
2016 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We report 8 additional genes with suggestive evidence of association, including the DNA repair genes PARP2 and MSH6 Finally, we observed an excess of rare truncation variants in 5 genes, including the DNA repair genes MSH6, BRCA1, and BRCA2 This adds to the growing body of evidence that DNA repair pathway defects may influence susceptibility to aggressive prostate cancer.
|
27486019 |
2016 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In all, 3 missense variants, PCTP, MCRS1, and ATRIP, demonstrated complete segregation and 1 missense variant, PARP2, demonstrated partial segregation with PC.
|
26585945 |
2016 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
In all, 3 missense variants, PCTP, MCRS1, and ATRIP, demonstrated complete segregation and 1 missense variant, PARP2, demonstrated partial segregation with PC.
|
26585945 |
2016 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We report 8 additional genes with suggestive evidence of association, including the DNA repair genes PARP2 and MSH6 Finally, we observed an excess of rare truncation variants in 5 genes, including the DNA repair genes MSH6, BRCA1, and BRCA2 This adds to the growing body of evidence that DNA repair pathway defects may influence susceptibility to aggressive prostate cancer.
|
27486019 |
2016 |